|Publication Type||Journal Article|
|Year of Publication||2013|
|Authors||Chapuy, B, McKeown, MR, Lin, CY, Monti, S, Roemer, MG, Qi, J, Rahl, PB, Sun, HH, Yeda, KT, Doench, JG, Reichert, E, Kung, AL, Rodig, SJ, Young, RA, Shipp, MA, Bradner, JE|
Diffuse large B cell lymphoma (DLBCL) is a biologically heterogeneous and clinically aggressive disease. Here, we explore the role of bromodomain and extra-terminal domain (BET) proteins in DLBCL, using integrative chemical genetics and functional epigenomics. We observe highly asymmetric loading of bromodomain 4 (BRD4) at enhancers, with approximately 33% of all BRD4 localizing to enhancers at 1.6% of occupied genes. These super-enhancers prove particularly sensitive to bromodomain inhibition, explaining the selective effect of BET inhibitors on oncogenic and lineage-specific transcriptional circuits. Functional study of genes marked by super-enhancers identifies DLBCLs dependent on OCA-B and suggests a strategy for discovering unrecognized cancer dependencies. Translational studies performed on a comprehensive panel of DLBCLs establish a therapeutic rationale for evaluating BET inhibitors in this disease.